特朗普拟对仿制药进口加征高额关税，Sandoz下跌3.2%

Oil hits 6-wk high as U.S.-Iran conflict, Saudi blockade fuel supply fears
Investing.com -- Sandoz stock fell 3.2% to trade at CHF 64.40 after U.S. President Trump announced that generic drug manufacturers will face 100% import tariffs starting in August 2028, escalating to 200% in August 2029 if production is not relocated to the United States.
As one of the world’s largest generics and biosimilars companies, Sandoz is squarely in the crosshairs of this policy, given its deep reliance on international manufacturing and its significant exposure to the U.S. market.
The tariff announcement compounds a cautious analyst environment that has been building around the stock. Jefferies trimmed its price target on Sandoz earlier in July, while Deutsche Bank had previously lowered its target to CHF 65 and maintained a Hold rating on the shares.
With the Q2 2026 earnings release scheduled for August 5, investors appear unwilling to add risk ahead of results that may need to address the tariff impact on guidance.
The broader market is also under modest pressure today, with the S&P 500 off 0.4% and the Nasdaq declining 0.9%, reflecting a wider risk-off tone partly driven by the same tariff escalation concerns.
Swiss pharmaceutical peers with significant generic drug exposure face a similar headwind, though companies whose revenues are more heavily weighted toward branded or patented medicines may be somewhat insulated.
Taken together, the combination of a direct policy threat to Sandoz’s generics segment, a cautious analyst consensus, and a soft broader market environment has pushed the stock to a session low of CHF 63.78 — leaving it roughly 14% below its 52-week high — as the market reprices the regulatory risk now hanging over the global generics industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.